Sigilon Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Sigilon Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2022.
  • Sigilon Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2023 was -$7.44M, a 47% increase year-over-year.
  • Sigilon Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2023 was -$30.8M, a 52.2% increase year-over-year.
  • Sigilon Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$43.7M, a 42.3% increase from 2021.
  • Sigilon Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$75.6M, a 43.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$43.7M +$32M +42.3% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-14
2021 -$75.6M -$23M -43.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 -$52.6M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.